Natural Alternative to Antibiotics
Brisbane, June 21, 2017 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
Oral therapeutics for gastrointestinal disease in livestock and humans
Detach(TM) - Natural, safe, non-antibiotic therapeutic that prevents and treats gastrointestinal diseases, including diarrhoea
- Meets the need to reduce the use of antibiotics and zinc oxide in animal production
- Unlike antibiotics and zinc oxide, Detach(TM) will not contribute to antimicrobial resistance (AMR)
Detach (TM) - Poised for swift market entry
Commercially validated, supported by demand
- A clear path to market: Launch in 2018
o Manufacturing complete at commercial scale and global supply confirmed
- Introduction of DetachTM is supported by industry, government, retailer & consumer demand
- Detach(TM) will be supplied in Australia via preexisting distribution channels (Australian pork industry is heavily consolidated)
- Focus now is on planning market launch
- Launch in Australia will provide leverage into Asia
- Global partnering interest for worldwide commercialisation
What Next?
Detach(TM) - A Pipeline in a Product
Other Detach(TM) presentations:
- Livestock: in-feed
- Livestock: in-water
Potential product extensions for the core components of Detach(TM)
Partnering Opportunities for:
- Human GI conditions (diarrhoea; inflammatory bowel disease; irritable bowel syndrome)
Anatara Investment Overview
- Experienced board and management team with proven track record
- Lead product, Detach(TM), has a clear route to market
o Commercially validated and proven efficacy
o Development strategy de-risked and revenues within 2 years
- Well funded - sufficient to launch Detach(TM) in key markets
- Product Pipeline - animal product leads to human product development for partnering opportunities
- Seasoned Operational Team
o Regulatory, Manufacturing, IP, Clinical Trials, R&D
About: Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing non-antibiotic, oral solutions for the prevention and control of gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.
